Surveillance in Barrett's oesophagus: A critical reappraisal

Scandinavian Journal of Gastroenterology, Supplement

Volumn 37, Issue 236, 2002, Pages 4-8

  Craanen, M E ^a   Blok, P ^a   Meijer, G A ^a   Meuwissen, S G M ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Barrett's oesophagus; Endoscopy; Oesophageal cancer; Surveillance

Indexed keywords

ANXIETY; BARRETT ESOPHAGUS; CANCER RISK; CONFERENCE PAPER; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DYSPLASIA; ESOPHAGUS CARCINOMA; FAMILY HISTORY; FOLLOW UP; HEALTH SURVEY; HUMAN; MEDICAL LITERATURE; MEDICAL RESEARCH; PRIORITY JOURNAL; PROSPECTIVE STUDY; ESOPHAGOSCOPY; ESOPHAGUS; ESOPHAGUS TUMOR; PATHOLOGY; REVIEW; SENSITIVITY AND SPECIFICITY; TIME;

BARRETT ESOPHAGUS; ESOPHAGEAL NEOPLASMS; ESOPHAGOSCOPY; ESOPHAGUS; FOLLOW-UP STUDIES; HUMANS; POPULATION SURVEILLANCE; SENSITIVITY AND SPECIFICITY; TIME FACTORS;

EID: 0035981654     PISSN: 00855928     EISSN: None     Source Type: Journal    
DOI: 10.1080/003655202320621373     Document Type: Conference Paper

References (25)

1. Sampliner RE and the Practice Parameters Committee of the American College of Gastroenterology. Practice guidelines on the diagnosis, surveillance, and therapy of Barrett's oesophagus. Am J Gastroenterol 1998;93: 1028-32.
2. Falk GW, Rice TW, Goldblum JR, Richter JE. Jumbo biopsy forceps protocol still misses unsuspected cancer in Barrett's oesophagus with high-grade dysplasia. Gastrointest Endosc 1999;49:170-6.
3. Levine DS. Management of dysplasia in the columnar-lined oesophagus. Gastroenterol Clin North Am 1997;26:613-24.
4. Schnell TG, Sontag SJ, Chejfec G, Aranha G, Metz A, O'Connell S, et al. Long-term nonsurgical management of Barrett's esophagus with high-grade dysplasia. Gastroenterology 2001; 120:1607-19.
5. Buttar N, Wang KK, Sebo TJ, Riehle DM, Krishnadath KK, Lutzke LS, et al. Extent of high-grade dysplasia in Barrett's esophagus correlates with risk of adenocarcinoma. Gastroenterology 2001;120:1630-9.
6. Reid BJ, Levine DS, Longton G, Blount PL, Rabinovitch PS. Predictors of progression to cancer in Barrett's esophagus: baseline histology and flow cytometry identify low- and high-risk patient subsets. Am J Gastroenterol 2000;95:1669-76.
7. Levine DS, Haggit RC, Blount PL, Rabinovitch PS, Rusch VW, Reid BJ. An endoscopic biopsy protocol can differentiate high-grade dysplasia from early adenocarcinoma in Barrett's esophagus. Gastroenterology 1993;105:40-50.
8. Zaninotto G, Parenti AR, Ruol A, Costantini M, Merigliano S, Ancona E. Oesophageal resection for high-grade dysplasia in Barrett's oesophagus. Br J Surg 2000;87:1102-5.
9. Reid BJ, Haggitt RC, Rubin CE. Observer variation in the diagnosis of dysplasia in Barrett's esophagus. Human Pathol 1988;19:166-78.
10. Guindi M, Riddell RH. The pathology of epithelial pre-malignancy of the gastrointestinal tract. Baillière's Best Pract Res Clin Gastroenterol 2001;15:191-210.
11. Rice TW, Falk GW, Achkar E, Petras RE. Surgical management of high-grade dysplasia in Barrett's esophagus. Am J Gastroenterol 1993;105:40-50.
12. Heitmiller RF, Redmond M, Hamilton SR. Barrett's esophagus with high-grade dysplasia. An indication for prophylactic esophagectomy. Ann Surg 1996;224:66-71.
13. Provenzale D. Endoscopic technology assessment in the 1990s: the role of decision analysis. In: Cotton PB, Tytgat GNJ, Williams CB, editors. Annual of gastrointestinal endoscopy, 8th ed. London: Current Science; 1995. p. 1-7.
14. Hameeteman W, Tytgat GNJ, Houthoff HJ, van den Tweel JG. Barrett's oesophagus: development of dysplasia and adenocarcinoma. Gastroenterology 1989;96:1249-56.
15. Drewitz DJ, Sampliner RE, Garewal HS. The incidence of adenocarcinoma in Barrett's esophagus: a prospective study of 170 patients followed 4.8 years. Am J Gastroenterol 1997:92: 212-5.
16. O'Connor JB, Falk GW, Richter JE. The incidence of adenocarcinoma and dysplasia in Barrett's esophagus: report on the Cleveland Clinic Barrett's esophagus registry. Am J Gastroenterol 1999;94:2037-42.
17. Shaheen NJ, Crosby MA, Bozymski EM, Sandler RS. Is there publication bias in the reporting of cancer risk in Barrett's esophagus. Gastroenterology 2000;119:333-8.
18. Lagergren J, Bergström R, Lindgren A, Nyrén O. Symptomatic gastroesophageal as a risk factor for esophageal adenocarcinoma. N Engl J Med 1999;340:825-31.
19. Provenzale D, Schmitt C, Wong JB. Barrett's esophagus: a new look at surveillance based on emerging estimates of cancer risk. Am J Gastroenterol 1999;94:2043-53.
20. Spechler SJ. Barrett's esophagus: an overrated cancer risk factor. Gastroenterology 2000;119:587-9.
21. Van Sandick JW, van Lanschot JJB, Kuiken BW, Tytgat GNJ, Offerhaus GJA, Obertop H. Impact of endoscopic biopsy surveillance of Barrett's oesophagus on pathological stage and clinical outcome of Barrett's carcinoma. Gut 1998;43:216-22.
22. Van der Veen AH, Dees J, van Blankensteijn JD, van Blankenstein M. Adenocarcinoma in Barrett's oesophagus: an overrated risk, Gut 1989;30;14-18.
23. Cameron A, Ott BJ, Payne WS. The incidence of adenocarcinoma in columnar-lined (Barrett's) esophagus. N Engl J Med 1985;313:857-9.
24. Rollins AM, Sivak MV. Potential new endoscopic techniques for the earlier diagnosis of pre-malignancy. Baillière's Best Pract Res Clin Gastroenterol 2001;15:227-47.
25. Georgakoudi I, Jacobson BC, van Dam J, Backman V, Wallace MB, Müller G, et al. Fluorescence, reflectance, and light-scattering spectroscopy for evaluating dysplasia in patients wilh Barrett's esophagus. Gastroenterology 2001;120:1620-9.